An $11 Billion Fund Just Bought These 3 Stocks

Roxanna Maglangit • 6 minute read
Reviewed by: Michael Douglass
Last updated Nov 20, 2026

@panumas nikhomkhai from Pexels via Canva, @Yakobchuk from Getty Images via Canva

Key Takeaways

  • Atreides Management manages $10.74 billion. Its latest 13F shows it more than doubled its stakes in Astera Labs and Meta Platforms in the third quarter and added 51% to Ciena.
  • All three stocks have fallen since Sept. 30, and each now trades below even the lowest analyst price target.
  • Meta’s AI spending turned its free cash flow negative last quarter, and Astera’s gross margin is slipping.
  • Astera Labs is the one the numbers back best, with revenue estimates rising as the stock has fallen.

Atreides Management’s 13F for the quarter ended Sept. 30, filed Nov. 16, shows seven new or added positions. The three biggest were Astera Labs (ALAB), Meta Platforms (META) and Ciena (CIEN), and the firm, which manages $10.74 billion, went big on each.

All three are down sharply since Sept. 30. Anyone following Atreides today pays far less than those shares were worth at quarter-end, and each stock trades below Wall Street’s lowest price target.

Astera Labs: the estimates keep climbing

Atreides held 2.46 million Astera shares at Sept. 30, worth $875 million, after more than doubling the stake. At 8.1% of its 13F stocks, it was the firm’s second-largest position. The stock is down 41% since then and sits 58% below its 52-week high.

The business has gone the other way. Management said at BMO’s conference that its Scorpio X switches alone should exit 2026 at an annualized run rate well above $1 billion. Analysts have since raised their revenue estimates to $3.39 billion for 2027 and $4.36 billion for 2028. Yet Astera trades at about 31x forward earnings, below the 44.5x low of its quarter-end readings since its 2024 IPO.

The Street’s average target has climbed from $197 a year ago to $344, 63% above the last close:

Line chart from TIKR of Astera Labs' analysts' consensus (mean) price target, $ per share, last year.
Astera Labs (ALAB): analysts’ consensus (mean) price target, $ per share, last year (TIKR)

The catch is margin. Non-GAAP gross margin fell to 73.7% in the second quarter from 76.4% in the first, on more hardware modules and Amazon’s warrants, and analysts expect 70.9% for 2027.

TIKR tracks 25 analysts on Astera Labs. How many say “Buy”?

See the full breakdown of Buy, Hold, and Sell ratings on Astera Labs, along with Wall Street’s revenue and earnings estimates, all in one place. More than 500,000 investors use TIKR to research stocks like this one. See Astera Labs’ Analyst Ratings

Meta: a discount with a capex bill attached

Atreides more than doubled its Meta stake to 872,413 shares, worth $633 million at Sept. 30. That’s 5.9% of its 13F stocks and its No. 3 position. The filing also lists call options with a notional value of $1.38 billion. Atreides wasn’t alone: Altimeter added 25% to its stake and Third Point opened a new one in the same quarter.

Meta is down 18% since Sept. 30, even though third-quarter revenue rose 26% to $64.6 billion and management guides the fourth quarter to $73 billion to $76 billion. At about 18x forward earnings, it trades below its five-year quarter-end average of 21.4x.

The reason is the build. Third-quarter capex of $34.9 billion topped $32.8 billion of operating cash flow, and consensus now has free cash flow bottoming at negative $48.0 billion in 2027. Analysts haven’t changed their minds much on the stock, though. The average target is about where it was a year ago:

Line chart from TIKR of Meta Platforms' analysts' consensus (mean) price target, $ per share, last year.
Meta Platforms (META): analysts’ consensus (mean) price target, $ per share, last year (TIKR)

At $848, it’s 42% above the last close, and even the lowest target, $650, sits above today’s price.

Ciena: the growth is there, and so are the targets

Atreides added 51% to its Ciena position, to 1.04 million shares worth $365 million at Sept. 30. That’s its No. 5 holding, at 3.4% of its 13F stocks. The stock is down 25% since then and sits 59% below its 52-week high, after a 15% drop in early November’s AI selloff.

Ciena’s business is still growing fast. It said in its fiscal third-quarter release that revenue rose 37% to $1.67 billion in the quarter ended Aug. 1, and adjusted EPS more than tripled to $2.11. It raised its fiscal 2026 revenue guide to $6.42 billion, plus or minus $50 million, from $6.3 billion.

Analysts have chased that growth hard. The average target has more than tripled in a year, to $512 from $155:

Line chart from TIKR of Ciena's analysts' consensus (mean) price target, $ per share, last year.
Ciena (CIEN): analysts’ consensus (mean) price target, $ per share, last year (TIKR)

That’s 95% above the last close, with the stock at about 25x forward earnings. The next check comes with its fiscal fourth-quarter report in December, which has to show margins can keep up with revenue.

If I could only buy one, it’s Astera

Not every big fund went the same way on Astera: Whale Rock Capital held none of its shares at Sept. 30, after owning 1.57 million at June 30. But the numbers back Atreides here. Astera’s revenue estimates have gone up since its last report while its multiple has come down, so investors are paying less for more expected growth than they were in June.

Meta’s discount is real, but consensus has its free cash flow negative through 2027, which makes it a longer wait. Ciena’s targets have run so far, so fast, that I’d want December’s report in hand first.

The risk with Astera is concentration. Its top three end customers were about 86% of 2025 revenue, so a pause by one hyperscaler would hurt. Management expects two or three more customers to join the two it ships Scorpio X to now. Revenue from a third customer in its fourth-quarter report early next year would go a long way toward confirming the case. Atreides’ next 13F, due in mid-February, will show whether it held on.

So what is Astera Labs stock actually worth?

TIKR lets you forecast the future price of any stock in less than a minute. Just enter a few assumptions into TIKR’s valuation model and see what Astera Labs could be worth. Start from Wall Street consensus estimates, or adjust the inputs to reflect your own view of the business. It’s free to use.

Value Astera Labs for free

Disclaimer:

Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any of the stocks mentioned. Thank you for reading, and happy investing!

Join thousands of investors worldwide who use TIKR to supercharge their investment analysis.

Sign Up for FREENo credit card required